nanotech investing Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases
nanotech investing Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors
nanotech investing Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers
nanotech investing Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
nanotech investing Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress
CORRECTION FROM SOURCE: Video - CEO Clips Bold Ventures Advances Exploration at Burchell and Highlights Ring of Fire
Bold Ventures Provides Update on Burchell Drilling Progress and Announces PDAC Participation at Booth #2610
